Inconsistent responses

After I discovered the possibility of a link between Depo-Provera and my tumour, I tried to broach the subject with my neurosurgical team – I simply wasn’t sure who else to ask. My emails went unanswered, and when I asked one surgeon about it in person, he responded that it wasn’t his area of expertise.

Many women I’ve since spoken to have faced similar responses from medical teams. “There’s just such a failure to listen,” says Sarah Samuel, a medical product liability solicitor at Fletchers, saying that, in many instances, women’s pain was “dismissed, minimised or normalised”.

In June of this year, a group of women visited the Scottish Parliament in Holyrood to discuss their concerns about a “medical scandal” with a cross-party group of Scottish Members of Parliament. Alongside the lawsuit, Lunt and Samuel are looking to take the case into the political sphere in England too. “We’re looking at running a campaign to put pressure on Westminster to raise awareness… [perhaps via] a public inquiry into what was known [about Depo-Provera] and when, and about the risks and why people weren’t warned about it.

“[We’re also looking at] whether there ought to be some kind of medical testing as a matter of routine for people that have been taking Depo-Provera for a long period of time.”

As a result of the BMJ study, rules and regulations around how Depo-Provera is prescribed have shifted in many other countries. The Austen Hays solicitor Rachel Bright tells me that in France, for instance, Depo-Provera is now prescribed only “if no other contraception works for you”. “If at any point during treatment you present with meningioma symptoms,” she says, “you are sent straight for an MRI.”

Currently, the NHS website advises that having the injection “for three years or longer may increase your chance of getting a type of brain tumour called meningioma” but stresses that “this type of brain tumour is rare, so your chance of getting it is still quite small”.

Ten months after my craniotomy, I live with life-changing side effects, as do many of the women I met while reporting this article: a fatigue that no amount of sleep seems able to shift; brain fog; headaches. The women I’ve spoken with also report suffering from mood swings, changes in balance and depth perception as well as sight and memory loss.

And, like them, I am left with questions. Why was I given a dose of Depo-Provera on the very day of my meningioma diagnosis, despite guidelines that advise otherwise? Why were my doctors unwilling to discuss the reported link between the drug and my tumour? And why have UK guidelines on Depo-Provera not been updated in line with those in other countries?

In the US, legal analysis of the scientific evidence surrounding the correlation between Depo-Provera and an increased risk of meningioma suggests that the research is strongly favourable to claimants pursuing cases against Pfizer.

That could prove highly significant for UK legal teams. The Fletchers team has been liaising with lawyers in the United States. “It’s much harder to succeed in England than it is in the US,” Samuel, the medical product liability solicitor at Fletchers, explains. “So that’s why it is really promising, having spoken to the US lawyers, that they’re saying the science is strong because that’s what we need in England in order to bring [Pfizer] to the table.”

Of course, no amount of money will bring back the lives we had before. Every woman I have spoken with who has joined the action against Pfizer has described losing not only her independence, but also her sense of self. I feel the same. None of us are the women we were before these medical horrors unfolded. But we are determined to raise the alarm as best we can – so that future generations, and other women, can make the informed choices that we were never given.

A spokesman for Pfizer said: Patient safety is our top priority. We conduct rigorous and continuous monitoring of all our medicines, including assessments of reported adverse events.

In 2024, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) initiated a Signal Management procedure to investigate the risk of meningioma with the long-term use of medroxyprogesterone acetate (MPA). Pfizer participated fully in this process. Although the relative risk of meningioma is significantly increased with the use of high-dose medroxyprogesterone acetate, the absolute risk is very small. Product information and patient information leaflet were updated to reflect this potential risk. In agreement with the MHRA, a direct healthcare professional communication was issued in 2024 to ensure healthcare professionals were directly informed.

We would encourage people to speak to their doctor, pharmacist or nurse if they have any concerns or experience any side effects.

A spokesman for the MHRA said: Our thoughts are with the women affected by meningioma, and we recognise the devastating impact this condition can have on their lives… 

Product information [and the Patient Information Leaflet were] updated in 2024 [and] early 2025 following studies which showed a very small risk of meningioma associated with use of high-dose MPA… However, we are aware that the risk of meningioma may not be well recognised amongst healthcare professionals or patients [and are] considering what further communications are needed. 

For the majority of people, the benefits of Depo-Provera outweigh the risk, but we advise anyone with any concerns to speak with their GP, pharmacist or contraceptive provider.